Last $0.47 USD
Change Today -0.025 / -5.05%
Volume 50.7K
GTHP On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

guided therapeutics inc (GTHP) Snapshot

Open
$0.48
Previous Close
$0.50
Day High
$0.48
Day Low
$0.47
52 Week High
08/15/13 - $0.75
52 Week Low
04/8/14 - $0.40
Market Cap
33.9M
Average Volume 10 Days
112.6K
EPS TTM
$-0.14
Shares Outstanding
72.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GUIDED THERAPEUTICS INC (GTHP)

Related News

No related news articles were found.

guided therapeutics inc (GTHP) Related Businessweek News

No Related Businessweek News Found

guided therapeutics inc (GTHP) Details

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company primarily develops LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. It is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.

30 Employees
Last Reported Date: 05/12/14
Founded in 1992

guided therapeutics inc (GTHP) Top Compensated Officers

Senior Vice President of Engineering and Secr...
Total Annual Compensation: $197.0K
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: $243.0K
Compensation as of Fiscal Year 2013.

guided therapeutics inc (GTHP) Key Developments

Guided Therapeutics, Inc. Receives Mexican Regulatory Approval for LuViva(R) Advanced Cervical Scan

Guided Therapeutics Inc. announced that LuViva(R) Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS). Cervical cancer is the leading cause of cancer in women of reproductive age in Mexico, and remains the second leading cause of cancer deaths in women. Each year, more than 13,900 cases of cervical cancer are diagnosed in Mexico, and more than 4,700 women die from the disease. The total population at risk for developing cervical cancer is nearly 36 million (ages 15-55), and cervical cancer remains a national health priority.

Guided Therapeutics, Inc Provides Sales Guidance for the Second Quarter of 2014 and Full Year 2014

Guided Therapeutics Inc. provided sales guidance for the second quarter of 2014 and full year 2014. For the second quarter of 2014, the company expected reporting that sales of LuViva reached $200,000, up over 60% from first quarter results. The company announced in line with expectations of LuViva sales of $1.0 million to $3.0 million for the full year 2014.

Guided Therapeutics, Inc Reports Unaudited Consolidated Results for the First Quarter Ended March 31, 2014; Reaffirms Earnings Guidance for 2014

Guided Therapeutics Inc. reported unaudited consolidated results for the first quarter ended March 31, 2014. Revenue and other income for the first quarter ended March 31, 2014 was approximately $141,000, including approximately $122,000 in sales of LuViva(R) devices and disposables, NIH grants totaling approximately $13,000, as well as other income from royalties of approximately $5,000. The net loss attributable to common stockholders for the first quarter of 2014 was approximately $1.6 million, or $0.02 per basic and diluted share, compared to approximately $1.8 million, or $0.03 per basic and diluted share, in the comparable quarter of 2013. Operating loss was $2,079,000 against $1,875,000 a year ago. The company believes it is on track to report product sales of $1 million to $3 million for 2014, in line with previous revenue guidance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GTHP:US $0.47 USD -0.025

GTHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $25.23 USD +0.02
View Industry Companies
 

Industry Analysis

GTHP

Industry Average

Valuation GTHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GUIDED THERAPEUTICS INC, please visit www.guidedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.